BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 27,803 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $325.71, for a total transaction of $9,055,715.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
John Oyler also recently made the following trade(s):
- On Wednesday, July 9th, John Oyler sold 27,802 shares of BeOne Medicines stock. The stock was sold at an average price of $253.38, for a total transaction of $7,044,470.76.
- On Monday, June 23rd, John Oyler sold 3,174 shares of BeOne Medicines stock. The stock was sold at an average price of $261.61, for a total transaction of $830,350.14.
BeOne Medicines Trading Up 3.2%
ONC stock traded up $10.69 during trading on Thursday, hitting $342.89. The company had a trading volume of 229,677 shares, compared to its average volume of 425,329. The firm has a market capitalization of $37.58 billion, a P/E ratio of -198.20 and a beta of 0.21. BeOne Medicines Ltd. - Sponsored ADR has a 52-week low of $170.99 and a 52-week high of $351.27. The company has a 50 day simple moving average of $305.23 and a 200-day simple moving average of $267.01. The company has a quick ratio of 1.72, a current ratio of 1.95 and a debt-to-equity ratio of 0.04.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.48 by $0.36. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. As a group, research analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.
Institutional Trading of BeOne Medicines
A number of institutional investors have recently modified their holdings of ONC. Parallel Advisors LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $59,000. Aaron Wealth Advisors LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $200,000. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $39,000. Avanza Fonder AB bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $199,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $3,491,000. 48.55% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on ONC shares. Wall Street Zen downgraded shares of BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Barclays initiated coverage on shares of BeOne Medicines in a report on Thursday. They set an "overweight" rating and a $385.00 target price on the stock. JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $321.00 to $345.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Guggenheim increased their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. Finally, Morgan Stanley increased their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a report on Friday, June 27th. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $336.30.
Read Our Latest Stock Report on ONC
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
